Status:
UNKNOWN
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
Lead Sponsor:
Prim. Prof. Dr. Oliver Findl, MBA
Conditions:
Central Serous Chorioretinopathy
Eligibility:
All Genders
21+ years
Phase:
PHASE2
PHASE3
Brief Summary
Central serous chorioretinopathy (CSC) is supposedly the fourth most common non-surgical retinopathy after age-related macular degeneration, diabetic retinopathy and branch retinal vein occlusion. The...
Detailed Description
Central serous chorioretinopathy (CSC) is supposedly the fourth most common non-surgical retinopathy after age-related macular degeneration, diabetic retinopathy and branch retinal vein occlusion. The...
Eligibility Criteria
Inclusion
- Patients suffering from untreated CSC for less than two months
- Age 21 and older
- Written informed consent
Exclusion
- Patients who have recently been treated with eplerenone
- Pregnancy or patients who are currently breast-feeding
- Patients who should not use eplerenone for any reason - an extensive internal medicine assessment will be performed in all patients prior to treatment start)
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02215330
Start Date
October 1 2014
End Date
September 1 2017
Last Update
August 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oliver Findl
Vienna, Austria, 1140